Prospective Study

Viral hepatitis prevalence in patients with active and latent tuberculosis

Hesam Ahmadi Nooredinvand, David W Connell, Mahmoud Asgheddi, Mohammed Abdullah, Marie O'Donoghue, Louise Campbell, Melissa I Wickremasinghe, Ajit Lalvani, Onn Min Kon, Shahid A Khan

Abstract

AIM: To assess the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection and association with drug induced liver injury (DILI) in patients undergoing anti-tuberculosis (TB) therapy.

METHODS: Four hundred and twenty nine patients with newly diagnosed TB - either active disease or latent infection - who were due to commence anti-TB therapy between September 2008 and May 2011 were included. These patients were prospectively tested for serological markers of HBV, HCV and human immunodeficiency virus (HIV) infections - hepatitis B core antigen (HBcAg), hepatitis B surface antigen (HBsAg), hepatitis B e antigen, IgG and IgM antibody to HBcAg (anti-HBc), HCV IgG antibody and HIV antibody using a combination of enzyme-linked immunosorbent assay, Western blot assay and polymerase chain reaction techniques. Patients were reviewed at least monthly during the TB treatment initiation phase. Liver function tests were measured prior to commencement of anti-TB therapy and 2-4 wk later. Liver function tests were also performed at any time the patient had significant nausea, vomiting, rash, or felt non-specifically unwell. Fisher’s exact test was used to measure significance in comparisons of proportions between groups. A P value of less than 0.05 was considered statistically significant.

RESULTS: Of the 429 patients, 270 (62.9%) had active TB disease and 159 (37.1%) had latent TB infection. 61 (14.2%) patients had isolated anti-HBc positivity, 11 (2.6%) were also HBSAg positive and 7
(1.6%) were HCV-antibody positive. 16/270 patients with active TB disease compared to 2/159 patients with latent TB infection had markers of chronic viral hepatitis (HBsAg or HCV antibody positive; \( P = 0.023 \)). Similarly the proportion of HBsAg positive patients were significantly greater in the active vs latent TB infection group (10/43 vs 1/29, \( P = 0.04 \)). The prevalence of chronic HBV or HCV was significantly higher than the estimated United Kingdom prevalence of 0.3% for each. We found no association between DILI and presence of serological markers of HBV or HCV. Three (5.3%) patients with serological markers of HBV or HCV infection had DILI compared to 25 (9.5%) patients without; \( P = 0.04 \).

CONCLUSION: Viral hepatitis screening should be considered in TB patients. DILI risk was not increased in patients with HBV/HCV.

Key words: Epidemiology; Hepatitis B; Hepatitis C; Tuberculosis; Drug induced liver injury

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Tuberculosis (TB) patients are not routinely tested for viral hepatitis in the United Kingdom. This is the first study from a European centre investigating the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients with TB. We found that chronic HBV and HCV prevalence in TB patients were 9 and 5 times greater than the estimated United Kingdom prevalence respectively. We also found that a significantly greater proportion of patients with active TB had chronic Hepatitis B compared with patients with latent TB infection. In our study there was no association between drug induced liver injury risk and presence of serological markers of HBV/HCV.

Nooredinvand HA, Connell DW, Asgheddi M, Abdullah M, O’Donoghue M, Campbell L, Wickremasinghe MJ, Lalvani A, Kon OM, Khan SA. Viral hepatitis prevalence in patients with active and latent tuberculosis. *World J Gastroenterol* 2015; 21(29): 8920-8926 Available from: URL: http://www.wjgnet.com/1007-9327/full/v21/i29/8920.htm DOI: http://dx.doi.org/10.3748/wjg.v21.i29.8920

INTRODUCTION

Tuberculosis (TB) is the leading cause of death from a curable infectious disease; in 2010, 1.45 million people died from TB and there were 8.8 million incident cases[1]. In the United Kingdom, the incidence of TB has steadily increased over the past two decades[2]. 7892 cases were reported in 2013, the majority in urban areas, with London accounting for 38% of those cases[2]. Over 80% of cases are non-United Kingdom born, and rates of TB in the non-United Kingdom born are approximately twenty-fold higher (86/100000) than those born in United Kingdom (4/100000)[2].

Standard four-drug anti-TB therapy for active disease (isoniazid, rifampicin, pyrazinamide and ethambutol) is associated with a range of significant side effects, the most serious of which is drug induced liver injury (DILI), which carries a mortality rate of up to 5%[3,4]. All anti-TB medications are potential causes of DILI[5]. The incidence of DILI from anti-TB treatment has been variably reported - between 2% and 28% - with a number of factors, including HLA phenotype and ethnicity, having been found to alter an individual’s risk for a hepatotoxic drug reaction[5,6]. The clinical presentation of DILI ranges from transient mild elevation of liver enzymes to fulminant liver failure, and a commonly used definition of DILI is an increase in serum alanine transaminase (ALT) greater than 3 or 5 times the upper limit of normal (ULN) with or without symptoms of acute hepatitis respectively[4].

The World Health Organization (WHO) estimates 240 million people worldwide are chronically infected with hepatitis B virus (HBV)[7]. Areas of high prevalence are similar to the global TB epidemiological “hotspots” and include sub-Saharan Africa and South Asia, where the prevalence is estimated to be between 8 and 20%[8]. The WHO estimate 3% of the World’s population are infected with hepatitis C virus (HCV), with 170 million being chronic carriers[9]. European countries report a prevalence of HCV in the general population of between 0.5%-2% and global areas of high prevalence again include Africa, particularly Egypt, and Asia[9]. In 2011 it was estimated that around 216000 individuals were the United Kingdom are chronically infected with HCV[10], the HPA and WHO estimate the United Kingdom prevalence of chronic HBV infection to be similar to this, at 0.3%. Chronic infection with HBV and/or HCV can cause progressive liver fibrosis and cirrhosis, liver failure and liver cancer. Effective therapies exist for both these viruses if they are diagnosed before advanced liver disease occurs, and early detection and treatment is important in minimising the health burden associated with chronic HBV and HCV. However, both these viruses are relatively asymptomatic and hence international liver associations recommend screening for HBV and HCV in high risk groups[11,12].

Several studies report an increased prevalence of viral hepatitis infection in TB patients[13-17] (Table 1). However, none of these studies have been performed in a European setting, so their applicability to the United Kingdom is not known. Although results are not universal, a number of international studies suggest that co-existing viral hepatitis may be a significant risk factor for DILI[13,18-22]. No studies on the prevalence of viral hepatitis in patients undergoing anti-TB therapy and the risk they add to DILI have been carried out in the United Kingdom or Europe, which have seen an increase in TB cases over recent years.
United Kingdom patients infected with TB are offered human immunodeficiency virus (HIV) screening\(^{[23]}\) due to an increased prevalence of co-infection, but viral hepatitis screening is not routinely offered and might be of value if the background prevalence of viral hepatitis is significant in patients with TB infection. London is a multicultural city with a significant number of immigrants from high endemic TB countries, suggesting that the prevalence of viral hepatitis infection may be higher than suspected.

**MATERIALS AND METHODS**

**Recruitment**

We recruited patients with newly diagnosed TB - either active disease or latent infection - at St. Mary’s Hospital, Imperial College Healthcare NHS Trust, London, who were due to commence standard anti-TB therapy for either stages of the infection between September 2008 and May 2011. The inclusion criteria were: newly diagnosed TB (active or latent); 18 years of age or above; ability to give informed consent; and no known history of chronic liver disease, viral hepatitis or HIV. No patients were immunosuppressed. Research ethics approval was obtained (No. 10/H0709/44).

**Clinical phenotyping**

TB infection was confirmed using the standard protocols in our clinic. Active TB infection was defined by clinical and radiological characteristics of symptomatic TB infection, with or without confirmatory culture information. If culture negative, then the patient was deemed to have had active TB if they made a satisfactory response to anti-tuberculosis therapy.

Latent TB infection was defined as an asymptomatic patient without radiographic evidence of active TB disease, and with a positive tuberculin skin test read at 48-72 h by an experienced nurse (defined as >5 mm induration if not BCG vaccinated or ≥15 mm if BCG vaccinated), subsequently confirmed with a positive interferon gamma release assay (either TSpot. TB (Oxford Immunotec, Oxford, United Kingdom), or Quantiferon Gold-in-Tube (Cellestis Ltd, Victoria, Australia)).

**Drug treatment**

For active disease, standard anti-tuberculous therapy in our clinic was rifampicin 600 mg/d (R), Isoniazid 300 mg/d (H), Pyrazinamide 25 mg/kg per day (Z) (these three jointly given as Rifater with the number of tablets dependent on weight; if the weight was sufficiently low, then the drugs were given separately as per guidelines\(^{[23]}\)), and Ethambutol 15 mg/kg per day (E) for 2 mo; followed by continuation rifampicin and isoniazid for a further 4 mo [8 mo if central nervous system (CNS) involvement]. Treating clinicians had the option to extend the initiation phase to 3 mo if the patient was persistently smear positive after one month of therapy and could extend the total duration of therapy if they felt the initial burden disease was high, on a case by case basis. Adjuvant steroid therapy was used in patients with pericardial or CNS disease, as per national guidelines\(^{[23]}\) and weekly pyridoxine 50mg orally was administered to all cases. Drug resistant cases were treated according to culture results as per national guidelines\(^{[23]}\).

For latent infection, patients were treated with 3 mo of Rifampicin 600mg daily (R) and Isoniazid 300 mg daily (H) (jointly given as Rifinah-300, two tablets daily), in keeping with standard United Kingdom practice.

**Data collection**

Patients’ demographic, serological and clinical data were collected following informed consent, from the London TB register, hospital clinical databases and clinical notes. Demographic information collected included age, gender and ethnicity. In addition to biochemical liver function tests, the following serological results were also collected: HIV antibody, hepatitis B core antigen (HBcAg), hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), IgG and IgM antibody to HBcAg (anti-HBc) and HCV IgG antibody (anti-HCV).

As per standard clinical protocol, patients were reviewed at least monthly during the TB treatment initiation phase. Liver function tests, including alanine transaminase (ALT) levels, were measured prior to commencement of anti-TB therapy and again 2-4 wk later. An ALT level of 40 IU/mL was taken as the upper limit of normal (ULN). DILI was defined as an ALT of greater than 80 IU/mL (2 × ULN), as defined by the Council for International Organisation of Medical Sciences (CIOM) DILI diagnostic scale\(^{[24]}\) with no other apparent cause for abnormal liver biochemistry. Severe DILI was defined at an ALT of 5 × ULN. Liver

### Table 1  Prevalence of hepatitis B virus and hepatitis C virus infection in tuberculosis patients in other studies \(n (%)\)

| Study (country)       | Study population             | Number of patients | HBsAg | HBsAg or anti-HBc | Anti-HCV |
|-----------------------|------------------------------|--------------------|-------|-------------------|---------|
| Kuniholm et al\(^{[16]}\) (Georgia) | All active TB patients       | 300                | 13 (4.3) | 27 (9)           | 36 (12) |
| Blal et al\(^{[15]}\) (Brazil)    | All active TB patients       | 209                | 6 (2.8)  | 56 (26.8)        | -       |
| Sirinak et al\(^{[17]}\) (Thailand) | HIV infected active TB patients | 849                | 70 (9)    | -                | 237 (31) |
| Aires et al\(^{[16]}\) (Brazil)   | All active TB patients       | 402                | 13 (3.2)  | 103 (25.6)       | -       |

HBsAg: Hepatitis B surface antigen; HCV: Hepatitis C virus; HBc: Hepatitis B core; TB: Tuberculosis.
function tests (LFTs) were performed at any time the patient had significant nausea, vomiting, rash, or felt non-specifically unwell.

HIV, HBV and HCV serological tests were performed at St Mary’s hospital pathology department. Enzyme-linked immunosorbent assay (ELISA) was used for detection of anti-HIV antibodies and confirmed by Western blot assay. Screening for HBV and HCV was conducted using second generation ELISA and confirmatory tests for HBsAg or HCV positive results included polymerase chain reaction techniques. Data were analysed using Prism 5 (GraphPad Software Inc.). Fisher’s exact test was used to measure significance in comparisons of proportions between groups. A P value of less than 0.05 was considered statistically significant.

RESULTS

Demographics
A total of 487 patients were recruited. 58 patients were excluded due to absent results or loss to follow up. Of the remaining 429 patients, 270 (62.9%) patients had active TB disease and 159 (37.1%) had latent TB infection. The mean age was 46.4 years and 51.3% of patients were male. The majority of patients were from the Indian Subcontinent and Sub Saharan Africa, together accounting for 59.7% of patients. 7.5% of patients were White British (Table 2).

Prevalence of HCV/HBV markers
Of 429 patients screened, 79 (18.4%) had positive serological markers for HBV or HCV infection. 61 (14.2%) had isolated anti-HBc antibody only; 11 (2.6%) were also HBsAg positive and 7 (1.6%) were positive for HCV IgG antibody. No patients had HBV/ HCV co-infection (Table 2). All patients positive for HBsAg and HCV Antibody were previously unknown to have a history of viral hepatitis.

Active TB disease vs latent TB infection
A similar proportion of patients in both groups had serological markers for HBV or HCV infection (49/270 active TB disease patients vs 30/159 latent TB infection patients; P = 0.9, Fisher’s exact test) (Table 3).

However, there was a significant difference between these groups with respect to chronic viral hepatitis: 16/270 patients with active TB disease compared to 2/159 patients with latent TB infection had markers of chronic viral hepatitis (HBsAg or HCV antibody positive; P = 0.023, Fisher’s exact test). Similarly, while there was no difference between the groups with respect to anti-HBc antibody positivity (43/270 in active TB disease group vs 29/159 in latent TB infection group; P = 0.59, Fisher’s exact test), the proportion of this group whose HBsAg was positive was significantly greater in the active TB patient group (10/43 in active TB patients vs 1/29 in latent TB infection group; P = 0.04, Fisher’s exact test).

A greater proportion of active TB disease patients were HCV seropositive compared to latent TB infection patients although this difference was not significant (6/270 active TB disease patients vs 1/159 latent TB infection patients; P = 0.27, Fisher’s exact test).

Viral hepatitis and HIV co-infection
Fifteen patients were already known to be HIV positive and a further 260 patients consented to HIV screening (245 active TB disease, 30 latent TB infection). Eleven patients were newly diagnosed with HIV meaning that, of the 275 patients, 26 (9.5%) were infected with HIV. Six (23.1%) of the HIV positive patients were co-
infected with HBV or HCV ($P = 0.26$, Fisher’s exact test).

**Pre-treatment ALT Levels**

Pre-treatment ALT levels were available in 399 patients, 71 of whom were HCV or anti-HBc positive (including those also positive for HBsAg). Fourteen (19.7%) of these patients had ALT levels of greater than 40 IU/mL compared to 61 (18.6%) patients negative for markers of HBV or HCV ($P = 0.87$, Fisher’s exact test). 13 (3.3%) patients had ALTs of greater than 2 × ULN (> 80 IU/mL), 3 of whom had ALTs of greater than 5 × ULN (> 200 IU/mL). All of these patients were negative for all markers for HBV and HCV.

**Post-treatment ALT Levels**

Post-treatment ALTs were documented in 396 patients, 72 of whom were HCV or anti-HBc positive (including those also positive for HBsAg). 16 (22.2%) of these patients had ALT elevation > 40 IU/mL compared to 89 (27.5%) patients negative for markers of HBV or HCV ($P = 0.31$, Fisher’s exact test). Six (8.3%) anti-HBc or HCV positive patients had ALT > 80 IU/mL compared to 33 (10.2%) patients without serological evidence of HBV or HCV ($P = 0.83$, Fisher’s exact test). Of the 13 patients with ALT > 200 IU/mL, only one was positive for HBV or HCV serological markers ($P = 0.48$, Fisher’s exact test).

**ALT levels post-treatment following normal pre-treatment levels**

Three hundred and twenty patients had normal (< 40 IU/mL) pre-treatment ALTs and also had follow-up LFTs; of these, 57 were positive for serological markers HBV or HCV. ALT elevation of greater than 80 IU/mL was seen in 3 (5.3%) patients with positive HBV or HCV serological markers, compared to 25 (9.5%) patients negative for serological markers HBV/HCV ($P = 0.44$, Fisher’s exact test). Twelve patients had ALT > 200 IU/mL of whom only one had serological evidence of HBV/HCV ($P = 0.70$, Fisher’s exact test). Five patients required interruption of treatment due to significantly elevated LFTs, none of whom had serological evidence of HBV/HCV. Overall, 13 (46.4%) of the 28 patients with DILI were above the age of 50 and 14 (50%) were male.

**DISCUSSION**

This is the first study from a European centre to investigate the prevalence of HBV and HCV in patients with TB. We found that 18.4% of newly diagnosed TB patients at a central London teaching hospital had markers of HBV or HCV; 2.6% of patients were HBsAg positive and 1.6% were anti-HCV Ab positive. All these diagnoses were new, and led to specialist referral with the aim of preventing long-term complications of chronic viral hepatitis.

Our study found that chronic HBV prevalence in TB patients was almost 9 times greater than the estimated overall United Kingdom prevalence. Similarly, the prevalence of HCV amongst TB patients in our study was over 5 times greater than the estimated United Kingdom prevalence of HCV. The majority of infected patients were of Indian Subcontinent or Black African origin, and our distribution of ethnicities was representative of London’s multi-racial TB population.

A recent study by Uddin and colleagues looked at the prevalence of HBV and HCV in South Asian immigrants in England attending community centres. 4998 individuals were screened and HBsAg or anti-HCV Ab was present in 1.2% and 1.6% of patients respectively, again higher than the national estimated prevalence. This may be partially explained by the older demographic screened in this study - attending mosques and temples - who are more likely to have been born and raised in South Asia and hence would be at a greater risk of acquiring infection with HBV/HCV at younger ages. The prevalence of chronic hepatitis B in our study was more than twice that found in the study by Uddin et al., reflecting the wider ethnic background to our population, and suggesting that screening for HBV and HCV may be more effective in health care settings which might capture a wider range of infected individuals.

Although HIV and HBV/HCV have similar risk factors, we found no significant association between these infections in our cohort of TB patients, suggesting that HIV seropositivity alone would not identify patients with unknown HBV/HCV.

Of note, a significantly greater proportion of patients with active TB had chronic Hepatitis B compared with patients with latent TB infection. The proportion of patients in the latent and active groups positive for anti-HBc did not differ, suggesting that whilst both groups had equal exposure to the virus, the group with active TB were more likely to fail to clear virus and remain sAg positive. This could be attributable to the relatively small number of latent TB patients in the study; alternatively, there may be shared pa-
theways of immune control, perhaps involving MHC I-restricted CD8 T cells important in both viral [28] and mycobacterial [29] control, which could link immune dysregulation in both Hepatitis B viral infection and M. tuberculosis infection.

It is relevant to note that, on further follow-up, none of the patients with HBsAg and/or Anti HCV positivity had cirrhosis, as chronic liver disease itself is a potential risk factor for acquiring TB.

Different studies have used varying definitions of hepatotoxicity; our study employed a range of thresholds, including one which is lower than the ATS guidelines on hepatotoxicity [29], with the aim of providing a more comprehensive analysis of the derangement in liver function that might occur in this population. Our study followed a standard protocol whereby LFTs were measured pre-treatment and 2-4 wk after treatment. Further LFTs were only measured if the patient had abnormal levels at week 2-4 or developed symptoms; it is therefore possible that patients developing asymptomatic DILI after 2-4 wk of treatment may have been missed, although this is not common [29]. As with a number of other studies, we found no association between HBV/HCV seropositivity and DILI at both a lower and a higher threshold for diagnosis [3, 16, 30], suggesting that anti-TB medication can generally be safely administered to those infected with HBV/HCV in settings similar to ours, provided liver function is regularly monitored. Although DILI tends to occur early in the course of anti-TB therapy, the prevalence of DILI in our study may potentially be underestimated as follow-up liver function tests were only checked once, unless clinically indicated.

It is also important to note that over 14% of patients undergoing anti-TB treatment were positive for anti-HBc. Without prophylactic anti-viral therapy, these patients are at risk of HBV reactivation and liver failure if they are immunosuppressed or undergo immunomodulatory therapy or chemotherapy in the future.

Without early detection and appropriate management, chronic infection with HBV or HCV can lead to cirrhosis, liver failure and liver cancer. The Health Protection Agency (United Kingdom) advises HCV screening in intravenous drug users (IVDU) and men who have sex with men [16] and the ATS recommends viral hepatitis screening in TB patients with risk factors such as IVDU, those born in endemic areas and in HIV positive individuals [29]. As the majority of TB patients in the United Kingdom are immigrants from areas of the world where HBV and HCV are relatively more highly prevalent, further studies to identify TB patients at highest risk of HBV/HCV co-infection, to investigate links between active TB and Hepatitis B, and to investigate the health economics of screening are warranted.

ACKNOWLEDGMENTS

We are grateful to the NIHR Biomedical Research Centre Funding scheme at Imperial College London for infrastructure support and the Centre for Respiratory Infection at Imperial College London.

REFERENCES

1 World Health Organisation. Global Tuberculosis Control 2011. Date last accessed: 2012 Sept 28. Available from: URL: http://www.who.int/tb/publications/global_report/en/  
2 Health Protection Agency. Tuberculosis in the United Kingdom: Annual report on tuberculosis surveillance in the United Kingdom 2013. Available from: URL: http://www.hpa.org.uk/Publications/InfectiousDiseases/Tuberculosis/1011TuberculosisintheUK/  
3 Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol 2008; 14: 6774-6785 [PMID: 19058303 DOI: 10.3748/wjg.14.6774]  
4 Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity;
conceivably up-to-date review. J Gastroenterol Hepatol 2008; 23: 192-202 [PMID: 17999546 DOI: 10.1111/j.1440-1746.2007.05207.x] 5 Yee D, Vaisillette C, Pelletier M, Paraison I, Rocher I,Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-1477 [PMID: 12569078 DOI: 10.1164/rccm.200206-626OC] 6 Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002; 166: 916-919 [PMID: 12359466 DOI: 10.1164/rccm.2108091] 7 World Health Organisation. Hepatitis B Fact Sheet No. 204. Date last updated: 2012 July. Date last accessed: 2012 Sept 28. Available from: URL: http://www.who.int/mediacentre/factsheets/fs204/en/ 8 World Health Organisation. Global Alert and Response: Hepatitis B. 2002. Date last accessed: 2012 Sept 28. Available from: URL: http://www.who.int/csr/disease/hepatitis/whoctdchylo200222/en/ 9 World Health Organisation. Prevention and Control of Viral Hepatitis: Framework for Global Action 2012. Available from: URL: http://www.who.int/csr/disease/hepatitis/GHP_framework.pdf 10 Health Protection Agency Centre for Infections. Hepatitis C in the United Kingdom: 2011 report. Date last accessed: 2012 Sept 28. Available from: URL: http://www.who.int/csr/disease/hepatitis/GHP_framework.pdf 11 Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374 [PMID: 19330875 DOI: 10.1002/hep.22759] 12 European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242 [PMID: 19054588 DOI: 10.1016/j.jhep.2008.10.001] 13 Patel PA, Voigt MD. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol 2002; 97: 1198-1201 [PMID: 12014728 DOI: 10.1111/j.1572-0241.2002.05704.x] 14 Kuninohm MH, Mark J, Aladavish L, Shubladze N, Khechinashvili G, Tsirtsvadze T, del Rio C, Nelson KE. Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patients. Int J Infect Dis 2008; 12: 51-56 [PMID: 17644020 DOI: 10.1016/j.ijid.2007.04.015] 15 Bial CA, Passos SR, Horn C, Georg I, Bonecini-Almeida MG, Rolla VC, De Castro L. High prevalence of hepatitis B virus infection among tuberculosis patients with and without HIV in Rio de Janeiro, Brazil. Eur J Clin Microbiol Infect Dis 2005; 24: 41-43 [PMID: 15616838 DOI: 10.1007/s00122-004-0727-2] 16 Srinak C, Kittiokraisak W, Pinjeesekulk D, Charsusontsri P, Luanloed P, Srisuwanvilai LO, Nateniyom S, Akksilp S, Likanonsakul S, Sattayawuthipong W, Burapat C, Varma JK. Viral hepatitis and HIV-associated tuberculosis: risk factors and TB treatment outcomes in Thailand. BAC Public Health 2008; 8: 245 [PMID: 18633892 DOI: 10.1186/1471-2458-8-245] 17 Aires RS, Matos MA, Lopes CL, Teles SA, Kozloowski AG, Silva AM, Filho JA, Lago BV, Mello FC, Martins RM. Prevalence of hepatitis B virus infection among tuberculosis patients with or without HIV in Goiânia City, Brazil. J Clin Virol 2012; 54: 327-331 [PMID: 22608842 DOI: 10.1016/j.jcv.2012.04.006] 18 de Castro L, do Brasil PE, Monteiro TP, Rolla VC. Can hepatitis B virus infection predict tuberculosis treatment liver toxicity? Development of a preliminary prediction rule. Int J Tuberc Lung Dis 2010; 14: 322-340 [PMID: 20132625] 19 Lee BH, Koh WJ, Choi MS, Sub GY, Chung MP, Kim H, Kwon OJ. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005; 127: 1304-1311 [PMID: 15821209 DOI: 10.1378/chest.127.4.1304] 20 Nader LA, de Mattos AA, Picom PD, Bassanesi SL, De Mattos AZ, Pineiro Rodrigo M. Hepatitis toxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor? Ann Hepatol 2010; 9: 70-74 [PMID: 20308724] 21 Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchken AE. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157: 1871-1876 [PMID: 9620920 DOI: 10.1164/ajrccm.157.6.9711039] 22 Chien JY, Huang RM, Wang JY, Ruan SY, Chien YJ, Yu CJ, Yang PC. Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment. Int J Tuberc Lung Dis 2010; 14: 616-621 [PMID: 20392336] 23 The National Collaborating Centre for Chronic Conditions. Tuberculosis (CG117). Clinical diagnosis and management of tuberculosis and measures for its prevention and control. 2011. Date last accessed: 2012 Sept 28. Available from: URL: http://guidance.nice.org.uk/CG117 24 Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin epidemiol 1993; 46: 1323-1330 [PMID: 8229110 DOI: 10.1016/0169-6996(93)90101-6] 25 Health Protection Agency Centre for Infections. Tuberculosis in London. 2010. Annual report on tuberculosis surveillance in London. 2012. Date last accessed: 2012 Sept 28. Available from: URL: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1314346024986 26 Uddin G, Shoeb D, Solaiman S, Marley R, Gore C, Ramsay M, Harris R, Ushiro-Lumb I, Moreea S, Alam S, Thomas HC, Khan S, Watt B, Pugh RN, Ramiaih S, Jervis R, Hughes A, Singhal S, Cameron S, Carman WF, Foster GR. Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin. J Viral Hepat 2010; 17: 327-335 [PMID: 20023207 DOI: 10.1111/j.1365-2893.2009.01240.x] 27 Radziewicz H, Uebelhorer L, Bengsch B, Grakoui A. Memory CD8+ T cell differentiation in viral infection: a cell for all seasons. World J Gastroenterol 2010; 17: 1869-1873 [PMID: 20762816] 28 Lalvan i A, Brookes R, Wilkinson RJ, Malin AS, Pathan AA, Andersen P, Dockrell H, Pasvol G, Hill AV. Human cytolytic and interferon-gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1998; 95: 270-275 [PMID: 9419365 DOI: 10.1073/pnas.95.1.270] 29 Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Pelouquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952 [PMID: 17021358 DOI: 10.1164/rccm.200510-1666ST] 30 Sigkumiyagam A, Sridhar S, Dharwai J, Abdel-Aziz D, Munro K, Connell DW, George PM, Molyneaux PL, Cooke GS, Burroughs AK, Lalvan i A, Wickremasinghe M, Kon OM. A comparison between two strategies for monitoring hepatic function during antituberculosis therapy. Am J Respir Crit Care Med 2012; 185: 653-659 [PMID: 22198973 DOI: 10.1164/rccm.201105-0580OC]
